ECSP003859A - COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS - Google Patents

COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS

Info

Publication number
ECSP003859A
ECSP003859A EC2000003859A ECSP003859A ECSP003859A EC SP003859 A ECSP003859 A EC SP003859A EC 2000003859 A EC2000003859 A EC 2000003859A EC SP003859 A ECSP003859 A EC SP003859A EC SP003859 A ECSP003859 A EC SP003859A
Authority
EC
Ecuador
Prior art keywords
treatment
composition
damaged
wound
agent
Prior art date
Application number
EC2000003859A
Other languages
Spanish (es)
Inventor
Paul Vincent Fish
Kevin Neil Dack
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcintosh
Nicholas Laurence Occleston
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003859A publication Critical patent/ECSP003859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Agente farmacéutico para uso en el tratamiento (por ejemplo, curación) de tejidos danados, tal como una herida, comprendiendo el agente farmacéutico una composición que comprende: (a) un factor de crecimiento;(b) un agente inhibidor;y, opcionalmente, (c) un vehículo, diluyente o excipiente farmaceúticamente aceptable;pudiendo el agente inhibidor inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido danado, tal como una herida.Pharmaceutical agent for use in the treatment (eg, healing) of damaged tissues, such as a wound, the pharmaceutical agent comprising a composition comprising: (a) a growth factor; (b) an inhibiting agent; and, optionally, (c) a pharmaceutically acceptable carrier, diluent or excipient; the inhibiting agent being able to inhibit the action of at least one specific adverse protein (for example, a specific protease) that is positively regulated in a damaged tissue environment, such as a wound.

EC2000003859A 1999-12-29 2000-12-28 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS ECSP003859A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
ECSP003859A true ECSP003859A (en) 2002-09-27

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003859A ECSP003859A (en) 1999-12-29 2000-12-28 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE456655T1 (en) 2000-10-16 2010-02-15 Genentech Inc TREATMENT METHODS USING WISP POLYPEPTIDES
WO2003013569A2 (en) * 2001-07-27 2003-02-20 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
WO2005065706A1 (en) 2003-12-31 2005-07-21 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
JP5361386B2 (en) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
KR20150072458A (en) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU1878201A (en) 2001-07-16
PE20011095A1 (en) 2001-10-27
UY26514A1 (en) 2001-07-31
AR027122A1 (en) 2003-03-12
GB9930768D0 (en) 2000-02-16
WO2001049309A3 (en) 2002-02-28
WO2001049309A2 (en) 2001-07-12
EP1242120A2 (en) 2002-09-25
CA2395487A1 (en) 2001-07-12
JP2003519193A (en) 2003-06-17
GT200000224A (en) 2002-06-15
CO5271671A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
BR0015605A (en) Composition and use
BR0014384A (en) Compounds for the treatment of ischemia
ES2176600T3 (en) DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION.
BR0200782A (en) Compounds for the treatment of ischemia
PA8468401A1 (en) COMPOUNDS FOR THE TREATMENT OF ISCHEMIA
AR020055A1 (en) A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A SUBSTANCE OF ACTIVE ENAMEL, USES OF SUCH COMPOSITION AND A METHOD TO PREPARE THE SAME.
BR0207760A (en) Pharmaceutical composition, use thereof, methods for treating pain and inflammation, and process for preparing a composition
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
ES2145913T3 (en) METALOPROTEASE INHIBITORS.
PT750618E (en) OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR030068A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAINFUL, INFLAMMATORY AND ULCEROUS CONDITIONS OF HUMED EPITELIAL SURFACES AS FOR EXAMPLE MUCOSITIS, STOMATITIS AND BEHCET SYNDROME
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
CO5580776A2 (en) STABLE PHARMACEUTICAL FORMULATION IN SOLUTION OF OXALIPLATIN
DE69507185T2 (en) Medicines used to treat osteoporosis
EA200500804A1 (en) Topical Anti-infective Compositions
AR007582A1 (en) COMPOSITION FOR WASHING THE SKIN, PROCEDURE FOR PREPARING IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, WHEN CASE, FOR COSMETIC TREATMENT OF THE SKIN.
ATE333896T1 (en) VASCULARIZATION INHIBITORS
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
ECSP003859A (en) COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS
ES2173923T3 (en) PROCEDURE THAT ALLOWS TO INACTIVATE A VIRUS IN THE PRESENCE OF A POLIETER AND AN AGENT.
ECSP930933A (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
ES2124983T3 (en) USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF RED SKIN STAINS OF NEUROGENOUS ORIGIN.
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.